Haleon (HLN) Stock Forecast, Price Target & Predictions
HLN Stock Forecast
Haleon stock forecast is as follows: an average price target of $9.15 (represents a -3.48% downside from HLN’s last price of $9.48) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
HLN Price Target
The average price target for Haleon (HLN) is $9.15 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $9.15 to $9.15. This represents a potential -3.48% downside from HLN's last price of $9.48.
HLN Analyst Ratings
According to 7 Wall Street analysts, Haleon's rating consensus is 'Buy'. The analyst rating breakdown for HLN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Haleon Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 08, 2024 | Rashad Kawan | Morgan Stanley | $9.15 | $8.29 | 10.37% | -3.48% |
The latest Haleon stock forecast, released on Apr 08, 2024 by Rashad Kawan from Morgan Stanley, set a price target of $9.15, which represents a 10.37% increase from the stock price at the time of the forecast ($8.29), and a -3.48% decrease from HLN last price ($9.48).
Haleon Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $9.15 |
| Last Closing Price | $9.48 | $9.48 | $9.48 |
| Upside/Downside | -100.00% | -100.00% | -3.48% |
In the current month, the average price target of Haleon stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Haleon's last price of $9.48. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 08, 2024 | Deutsche Bank | Hold | Hold | Hold |
| Sep 20, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 06, 2024 | Goldman Sachs | - | Neutral | Downgrade |
| Aug 05, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Aug 02, 2024 | Barclays | Overweight | Overweight | Hold |
| Aug 01, 2024 | Jefferies | Buy | Buy | Hold |
| Jul 09, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Jul 09, 2024 | Barclays | Overweight | Overweight | Hold |
| May 02, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| Apr 17, 2024 | HSBC | - | Buy | Initialise |
Haleon's last stock rating was published by Deutsche Bank on Oct 08, 2024. The company gave HLN a "Hold" rating, the same as its previous rate.
Haleon Financial Forecast
Haleon Revenue Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $2.99B | $3.79B |
| Avg Forecast | $7.08B | $7.06B | $3.29B | $6.80B | $3.08B | $2.79B | $3.70B | $7.03B | $7.06B | $3.29B | $3.19B | $3.08B |
| High Forecast | $10.37B | $10.36B | $4.83B | $9.96B | $4.52B | $4.08B | $5.42B | $10.31B | $10.36B | $4.83B | $4.68B | $4.52B |
| Low Forecast | $5.40B | $5.40B | $2.51B | $5.19B | $2.35B | $2.13B | $2.82B | $5.37B | $5.40B | $2.51B | $2.44B | $2.35B |
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.94% | 1.23% |
Haleon's average Quarter revenue forecast for Jun 23 based on 1 analysts is $3.29B, with a low forecast of $2.51B, and a high forecast of $4.83B. HLN's average Quarter revenue forecast represents a 10.22% increase compared to the company's last Quarter revenue of $2.99B (Mar 23).
Haleon EBITDA Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $637.00M | $619.00M |
| Avg Forecast | $1.38B | $1.37B | $639.88M | $1.32B | $599.03M | $541.54M | $718.82M | $1.37B | $1.37B | $639.88M | $620.51M | $599.03M |
| High Forecast | $2.02B | $2.01B | $938.14M | $1.94B | $878.25M | $793.95M | $1.05B | $2.01B | $2.01B | $938.14M | $909.73M | $878.25M |
| Low Forecast | $1.05B | $1.05B | $488.72M | $1.01B | $457.52M | $413.61M | $549.01M | $1.04B | $1.05B | $488.72M | $473.92M | $457.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.03% |
1 analysts predict HLN's average Quarter EBITDA for Jun 23 to be $639.88M, with a high of $938.14M and a low of $488.72M. This is 0.45% upper than Haleon's previous annual EBITDA (Mar 23) of $637.00M.
Haleon Net Income Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $389.00M | $198.00M |
| Avg Forecast | $1.63B | $1.59B | $884.58M | $1.69B | $1.53B | $674.18M | $823.56M | $1.69B | $1.66B | $885.95M | $742.01M | $14.24B |
| High Forecast | $2.62B | $2.56B | $1.42B | $2.72B | $2.46B | $679.15M | $1.32B | $2.71B | $2.67B | $1.42B | $1.19B | $22.88B |
| Low Forecast | $1.13B | $1.10B | $612.92M | $1.17B | $1.06B | $669.22M | $570.64M | $1.17B | $1.15B | $613.87M | $514.14M | $9.87B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.52% | 0.01% |
Haleon's average Quarter net income forecast for Jun 23 is $885.95M, with a range of $613.87M to $1.42B. HLN's average Quarter net income forecast represents a 127.75% increase compared to the company's last Quarter net income of $389.00M (Mar 23).
Haleon SG&A Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $1.14B | $1.51B |
| Avg Forecast | $2.93B | $2.93B | $1.36B | $2.82B | $1.28B | $1.15B | $1.53B | $2.91B | $2.93B | $1.36B | $1.32B | $1.28B |
| High Forecast | $4.30B | $4.29B | $2.00B | $4.13B | $1.87B | $1.69B | $2.25B | $4.27B | $4.29B | $2.00B | $1.94B | $1.87B |
| Low Forecast | $2.24B | $2.23B | $1.04B | $2.15B | $974.73M | $881.17M | $1.17B | $2.23B | $2.23B | $1.04B | $1.01B | $974.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.86% | 1.18% |
Haleon's average Quarter SG&A projection for Jun 23 is $1.36B, based on 1 Wall Street analysts, with a range of $1.04B to $2.00B. The forecast indicates a 20.11% rise compared to HLN last annual SG&A of $1.14B (Mar 23).
Haleon EPS Forecast
| Mar 26 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | $0.08 | $0.04 |
| Avg Forecast | $0.18 | $0.17 | $0.10 | $0.18 | $0.17 | $0.07 | $0.09 | $0.18 | $0.18 | $0.10 | $0.08 | $1.55 |
| High Forecast | $0.28 | $0.28 | $0.15 | $0.29 | $0.27 | $0.07 | $0.14 | $0.29 | $0.29 | $0.15 | $0.13 | $2.48 |
| Low Forecast | $0.12 | $0.12 | $0.07 | $0.13 | $0.12 | $0.07 | $0.06 | $0.13 | $0.12 | $0.07 | $0.06 | $1.07 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.03% |
According to 1 Wall Street analysts, Haleon's projected average Quarter EPS for Jun 23 is $0.10, with a low estimate of $0.07 and a high estimate of $0.15. This represents a 14.49% increase compared to HLN previous annual EPS of $0.08 (Mar 23).
Haleon Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $2.41 | $16.00 | 563.90% | Buy |
| EBS | Emergent BioSolutions | $8.88 | $51.50 | 479.95% | Buy |
| ELAN | Elanco Animal Health | $13.44 | $26.50 | 97.17% | Buy |
| LNTH | Lantheus | $86.45 | $146.25 | 69.17% | Buy |
| ZTS | Zoetis | $175.67 | $227.71 | 29.62% | Buy |
| CTLT | Catalent | $59.00 | $74.25 | 25.85% | Hold |
| BHC | Bausch Health Companies | $8.19 | $10.00 | 22.10% | Hold |
| NBIX | Neurocrine Biosciences | $123.29 | $147.35 | 19.51% | Buy |
| TEVA | Teva Pharmaceutical Industries | $17.03 | $20.00 | 17.44% | Buy |
| VTRS | Viatris | $13.13 | $13.75 | 4.72% | Hold |
| PETQ | PetIQ | $30.98 | $31.00 | 0.06% | Buy |
| HCM | HUTCHMED (China) | $17.96 | $17.50 | -2.56% | Buy |
| HLN | Haleon | $9.48 | $9.15 | -3.48% | Buy |